Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Utah.
Press releases published on August 27, 2025
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 27, 2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following …
Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007
GlobeNewswire
·
August 27, 2025
— Financing led by Fidelity Management …
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 27, 2025
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management …
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
August 27, 2025
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the …
TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
GlobeNewswire
·
August 27, 2025
LONDON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- TREOS Bio Ltd., a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, today announced the execution of clinical collaboration agreements with Charité – …
NEW: Food Allergy Emergency Care Plan Empowers Self-Care and Reduces Health Care Costs
GlobeNewswire
·
August 27, 2025
Washington, DC, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) announces the availability of the first validated food allergy anaphylaxis action plan, including versions for children under age 3 and children age 3 and …
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 27, 2025
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and …
Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences
GlobeNewswire
·
August 27, 2025
BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and …
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
GlobeNewswire
·
August 27, 2025
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a virtual KOL event …
Mesoblast Financial Results and Corporate Update Webcast
GlobeNewswire
·
August 27, 2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year …
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
GlobeNewswire
·
August 27, 2025
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary …
Bigelow Butterfly Pea Flower Teas Now Expanding Nationwide
GlobeNewswire
·
August 27, 2025
Fairfield, Connecticut, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bigelow Tea, a third-generation family and woman-owned leader in the U.S. tea market, is now bringing its trending, highly sought after Bigelow Butterfly Pea Flower line to major retailers …
Voting Rights and Shares Capital of the Company
GlobeNewswire
·
August 27, 2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq …
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
GlobeNewswire
·
August 27, 2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 27 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext Compartiment : B Code ISIN : …
BioVersys Receives EMA Orphan Designation for the Combination of Alpibectir and Ethionamide for the Treatment of Tuberculosis
GlobeNewswire
·
August 27, 2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Orphan designation is granted to drug candidates addressing life-threatening or chronically debilitating diseases affecting fewer than 5 in 10’000 EU residents …
Immuron partners with InvestorHub
GlobeNewswire
·
August 27, 2025
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital …
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 27, 2025
SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …